Tolcapone Production Cost Reports

The report provides a detailed analysis essential for establishing a Tolcapone production plant. It encompasses all critical aspects necessary for Tolcapone production, including the cost of Tolcapone production, Tolcapone plant cost, Tolcapone production costs, and the overall Tolcapone production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Tolcapone production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Tolcapone is a medication that is used in Parkinson's disease to improve the effectiveness of levodopa therapy. It works by stopping the enzyme catechol-O-methyltransferase (COMT), which breaks down levodopa in the body. This inhibition increases the availability of levodopa both in the brain and periphery, resulting in a longer duration of symptom relief. It has a longer half-life and better brain penetration compared to similar drugs, which makes it more effective. Its use requires careful monitoring because of the risks of liver toxicity.

It is useful for patients experiencing motor fluctuations despite treatment with levodopa alone or other adjunctive therapies. It also shows improvements in non-motor symptoms and cognitive function in some patients on tolcapone.

The Tolcapone market is driven by the increasing global prevalence of Parkinson's disease. The rising awareness of the disease and its treatments, and advancements in healthcare infrastructure, boost its demand. The ongoing research to improve drug formulations and efficacy also fuels market growth.

The growing focus on its hospital and clinic usage, because of the need for specialised administration and monitoring, makes it a popular product. The industrial Tolcapone procurement is affected by strict regulatory requirements because of potential liver toxicity, raw material availability, and production capabilities. The changes in price, competition from substitute drugs, and supply chain disruptions also influence market dynamics.

Raw Material for Tolcapone Production

According to the Tolcapone production plant project report, the key raw materials used in the production of Tolcapone include 2-Methoxy Anisole-(4-Methyl Benzoyl Chloride-)-Aluminium Chloride-Melamine Nitrate-Hydrobromic Acid-Acetic Acid.

Manufacturing Process of Tolcapone

The extensive Tolcapone production cost report consists of the following major industrial production process:

1. From 2-Methoxy Anisole and 4-Methyl Benzoyl Chloride: The production process for tolcapone involves a reaction between 2-methoxy anisole and 4-methyl benzoyl chloride. In this process, 2-methoxy anisole reacts with 4-methyl benzoyl chloride in the presence of aluminium chloride. This results in the formation of 4-hydroxy-3-methoxy-4-methyl benzophenone, which goes through nitration using melamine nitrate as a nitrating agent to give nitro benzophenone. Finally, demethylation is carried out using hydrobromic acid in acetic acid, which leads to the formation of pure tolcapone.

Tolcapone is a yellow to greenish crystalline powder that has the molecular formula C14H11NO5 and a molecular weight of 273.24 g/mol. It has a melting point between 142 to 146 degree Celsius and is almost insoluble in water and acids but soluble in alkaline solutions. It is odourless and non-hygroscopic. It has two phenolic groups and a nitro group on its benzophenone structure, contributing to its biochemical activity as a catechol O-methyltransferase (COMT) inhibitor. It is moderately lipophilic, which makes it penetrate the blood-brain barrier effectively. It exists in its monoanionic form at physiological pH (7.4), with pKa values around 4.5 and 10.6 for its phenolic groups. It has a low aqueous solubility but strong protein binding in plasma. All these physical and chemical properties make it useful as a centrally acting drug to improve dopamine activity in Parkinson's disease treatment.